Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

Gerd R Burmester; Stanley B Cohen; Kevin L Winthrop; Peter Nash; Alan D Irvine; Atul Deodhar; Eduardo Mysler; Yoshiya Tanaka; John Liu; Ana P Lacerda; Hannah Palac; Tim Shaw; Philip J Mease; Emma Guttman‑Yassky

doi:10.1136/rmdopen-2022-002735

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest Content

Archive

For authors

About

Podcasts
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF

Inflammatory arthritis

Original research

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Burmester GR, Cohen SB, Winthrop KL, et al

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

RMD Open 2023;9:e002735. doi: 10.1136/rmdopen-2022-002735

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password